1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6DD13E13876960180852584BE00709ACF
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/DD13E13876960180852584BE00709ACF?OpenDocument
18
19OpenDocument
203.236.222.124
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Patient Focused Services Patient Advocacy Groups

Document Excerpt: Patient Advocacy 2020: Regulatory Impact, Technology Utilization and Lessons Learned Outside of the United States

DB Image

ID: MD-689


Features:

25 Info Graphics

5 Data Graphics

20 Metrics

30 Narratives


Pages/Slides: 4


Published: 2019


Delivery Format: Online PDF Document


 

License Options:


Download FREE Excerpt

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
To download this excerpt, click "add to cart" on the right.


To return to the study abstract to purchase the full study - click here

This excerpt includes research findings and metrics from document #5589 "Patient Advocacy 2020: Regulatory Impact, Technology Utilization and Lessons Learned Outside of the United States".


Industries Profiled:
Pharmaceutical; Manufacturing; Biotech; Consumer Products; Diagnostic; Medical Device; Research; Clinical Research; Health Care; Communications; Medical; Biopharmaceutical; Laboratories


Companies Profiled:
AbbVie; Astellas; Bayer; BioMarin; Bluebird Bio; Covance; Bionical Emas; Lundbeck; Janssen; Merck; Merck Serono; NexGen Healthcare Communications; Novartis; Parkway Pantai; Sanofi; Servier; Shire; Spark Therapeutics; Takeda Pharmaceuticals; UCB Pharma; Tillotts Pharma; Teva Pharmaceutical Industries Ltd

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.